LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Kodu・Aktsiate loetelu・Verve Therapeutics Inc

Verve Therapeutics Inc

Suletud

4.64 8.41

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

4.22

Max

4.7

Põhinäitajad
By Trading Economics
Sissetulek	98K -50M
Müük	6.2M 13M
Aktsiakasum	-0.58
Kasumimarginaal	-382.531
Töötajad	274
EBITDA	789K -54M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+485.85% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	6. aug 2025

Turustatistika
By TradingEconomics
Turukapital	-207M 388M
Eelmine avamishind	-3.77
Eelmine sulgemishind	4.64

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

4.1501 / 5.16 Toetus ja vastupanu

Verve Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

15. mai 2025, 22:52 UTC

Tulu

Suurimad hinnamuutused turgudel

Virgin Galactic Shares Rise on Commercial Spaceflight Plans, Narrower 1Q Loss

15. mai 2025, 20:37 UTC

Peamised uudised

Tulu

Applied Materials Logs Higher 2Q Profit, Revenue as Customer Demand Remains Unchanged

16. mai 2025, 00:00 UTC

Market Talk

Xero Bull Stays Positive on Cost Outlook -- Market Talk

15. mai 2025, 23:47 UTC

Market Talk

Gold Consolidates; Likely Supported by Signs of Disinflation -- Market Talk

15. mai 2025, 23:38 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15. mai 2025, 23:38 UTC

Market Talk

Nikkei May Edge Higher, Tracking Gains Across Most U.S. Equity Markets -- Market Talk

15. mai 2025, 23:14 UTC

Peamised uudised

Walmart Becomes Biggest Retailer Yet to Pass Through Tariff Price Increases -- 4th Update

15. mai 2025, 22:46 UTC

Peamised uudised

Omandamised, ülevõtmised, äriostud

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

15. mai 2025, 22:46 UTC

Omandamised, ülevõtmised, äriostud

Bayer Working With Restructuring Advisers Latham, AlixPartners to Explore Options for Monsanto -- WSJ

15. mai 2025, 22:46 UTC

Omandamised, ülevõtmised, äriostud

Bayer Exec Says Company Committed to Resolving Roundup Lawsuits in 18 Months -- WSJ

15. mai 2025, 22:46 UTC

Omandamised, ülevõtmised, äriostud

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

15. mai 2025, 21:58 UTC

Tulu

Applied Materials Earnings Beat Expectations. Why the Stock Is Down. -- Barrons.com

15. mai 2025, 21:24 UTC

Tulu

Cava's Earnings Beat Expectations. Growth Was Strong Despite Tariff Fears. -- Barrons.com

15. mai 2025, 20:56 UTC

Market Talk

U.S. Spending Downturn Could Lie Ahead -- Market Talk

15. mai 2025, 20:54 UTC

Market Talk

Tulu

Applied Materials CFO Says Demand Stable Despite Tariffs, Macro -- Market Talk

15. mai 2025, 20:54 UTC

Tulu

Applied Materials Investing to Support Semiconductor Market of More Than $1T by End of Decade, Financial Chief Says

15. mai 2025, 20:51 UTC

Tulu

Applied Materials Financial Chief: Long-Term Secular Growth Drivers Remain Intact

15. mai 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

15. mai 2025, 20:50 UTC

Omandamised, ülevõtmised, äriostud

Berkshire Sells Financial Stocks, Doubles Constellation Stake, Holds Steady on Apple -- WSJ

15. mai 2025, 20:50 UTC

Tulu

Applied Materials' Customer Investments Continue at Expected Rate and Pace, Financial Chief Says

15. mai 2025, 20:47 UTC

Tulu

Applied Materials Not Currently Seeing Large Changes in Customer Demand, CEO Says

15. mai 2025, 20:47 UTC

Tulu

Applied Materials Sees Revenue From Advanced DRAM Customers to Grow 40% in FY25, CEO Says

15. mai 2025, 20:47 UTC

Tulu

Applied Materials Grew Faster Than Peers in Markets Outside China in 2Q, CEO Says

15. mai 2025, 20:47 UTC

Tulu

Applied Materials Underperformed Market in China in 2Q Due to Restrictions on U.S. Companies, CEO Says

15. mai 2025, 20:37 UTC

Tulu

SOS Ltd: Growth Was Fueled by Robust Domestic Demand and Expansion of Pdt Portfolio to Include Rubber and Coal >SOS

15. mai 2025, 20:37 UTC

Tulu

SOS Ltd: Cryptocurrency Mining Rev Declined to $9.3M From $18.9M in FY23, Dip Was Attributed to the Temporary Shutdown of Texas Mining Facility for Upgrades During 1H 2024 >SOS

15. mai 2025, 20:37 UTC

Tulu

SOS Ltd: FY24 Significant Yr-over-Yr Increase in Commodity Trading Rev, Which Soared to $214.3M FY24, 92.6% of Total Rev Up From 74.0% in FY23 >SOS

15. mai 2025, 20:37 UTC

Tulu

SOS Ltd: Cryptocurrency Mining Rev Halves as SOS Focuses on Facility Upgrades and Commodity Expansion >SOS

15. mai 2025, 20:26 UTC

Peamised uudised

Trump Presses Apple to Bring iPhone Manufacturing to America. Wall Street Shrugs. -- WSJ

15. mai 2025, 20:25 UTC

Tulu

Deere Stock Jumps on Guidance Cut. Here's Why. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Verve Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

485.85% tõus

12 kuu keskmine prognoos

Keskmine 25.25 USD 485.85%

Kõrge 39 USD

Madal 15 USD

Põhineb 10 Wall Streeti analüütiku instrumendi Verve Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

10 ratings

Osta

Hoia

Müü

Põhineb 10 analüütiku instrumendi Verve Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

4.1501 / 5.16Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bearish.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Verve Therapeutics Inc

Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.